🔴 Summit Therapeutics is trading 11% down today as biotech and major indexes sell off

Summit Therapeutics is trading at $14.46, down 10.61%, amid broad market and biotech weakness.

• The company reported a third-quarter GAAP net loss of $208.4 million, while its loss per share was narrower than analysts expected.
• Biotech ETF XBI fell 5.19%, alongside steep losses across major indexes.
• The earnings release also highlighted a $2 billion AstraZeneca investment and an FDA decision date of November 14, 2026.